Hindawi Mediators of Inflammation Volume 2022, Article ID 9895309, 2 pages https://doi.org/10.1155/2022/9895309



Corrigendum

Corrigendum to "Anti-Interleukin-16-Neutralizing Antibody Attenuates Cardiac Inflammation and Protects against Cardiac Injury in Doxorubicin-Treated Mice"

Jianwei Zhang,¹ Zicong Yang,² Zhishan Liang,² Mengjie Wang,² Changxing Hu,² Chao Chang ¹D,³ Lei Shi,² Qingwei Ji ¹D,² and Ling Liu²

Correspondence should be addressed to Qingwei Ji; jqw124@163.com and Ling Liu; gxliu@126.com

Received 6 April 2022; Accepted 6 April 2022; Published 29 April 2022

Copyright © 2022 Jianwei Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

In the article titled "Anti-Interleukin-16-Neutralizing Antibody Attenuates Cardiac Inflammation and Protects against Cardiac Injury in Doxorubicin-Treated Mice" [1], the image for IL-16 in Figure 1 has been duplicated and presented as the image for GAPDH in Figure 1.

The authors have explained that this duplication was introduced in error while uploading files during the production of their article and have highlighted the correct images have been present in their files for the duration of peer review.

The correct Figure 1 appears below.

¹Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung, And Blood Vessel Diseases, The Key Laboratory of Remodeling-related Cardiovascular Disease, Ministry of Education, Beijing 100029, China ²Department of Cardiology, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, China

³Department of Cardiology, Handan First Hospital, Handan, Hebei, China

2 Mediators of Inflammation




FIGURE 1: Effects of DOX on cardiac IL-16 expression. (a, b) Cardiac IL-16 expression and serum IL-16 levels were measured in the control and DOX groups (nonparametric test). (c) Cardiac IL-16 expression in the 2 groups was determined by immunofluorescence staining (200x). (d) Effects of DOX on IL-16 mRNA expression in CTLL-2 T lymphocytes (Lyms), RAW264.7 macrophages (Møs), DC2.4 dendritic cells (DCs), and HL-1 cardiomyocytes (CMs) (Student's t-test). (e) Double immunofluorescence staining with anti-F4/80 and anti-IL-16 in DOX-induced mice (200x). N = 5 in each group. *p < 0.05 vs. the control group.

References

[1] J. Zhang, Z. Yang, Z. Liang et al., "Anti-Interleukin-16-Neutralizing Antibody Attenuates Cardiac Inflammation and Protects against Cardiac Injury in Doxorubicin-Treated Mice," *Mediators of Inflammation*, vol. 2021, Article ID 6611085, 10 pages, 2021.